Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 10,201–10,300 of 15,747
Simone, S., Pesce, F., Fontò, G., Pronzo, V., Pontrelli, P., Conserva, F., Schirinzi, A., Casanova, A., Gallo, P., Rossini, M., et al. (2023) · Journal of Nephrology · doi:10.1007/s40620-023-01650-8 · Cited by 5
Luo, X., Lessomo, F. Y. N., Yu, Z., & Xie, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145081 · Cited by 4
SARS-CoV-2 Infection upon Leaving the Tokyo 2020 Olympic and Paralympic Games
Urashima, M., Takao, H., Sakano, T., Takeshita, K., Yoshida, M., Nakazawa, Y., Kawai, M. J., & Murayama, Y. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0724-22 · Cited by 4
““Full vaccination” was defined as follows: two doses, in any combination, of BNT162b2 (Pfizer-BioNTech) (7), mRNA-1273 (Moderna) (8), ChAdOx1 nCoV-19 vaccine (AstraZeneca) (9), Gam-COVID-Vac (Sputnik V) (10), CoronaVac (Sinovac) (11), or NVX-CoV2373 (Novavax) (12) or at least one dose of the Ad26.”
MethodKim, Y., Shim, H., Jeong, H., & Park, Y. (2022) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346221141173 · Cited by 4
Kato, H., Kurosawa, T., Horikawa, K., Kimura, Y., Miyakawa, K., Ryo, A., & Goto, A. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2278376 · Cited by 4
Alqahtani, S., Abdulqader, A. A. A., Mashhour, W. A. A., Aldawood, Z., Almasari, O., Alotaibi, T., Alghamdi, Z. M., Alzahrani, I. M., & Albaloushi, N. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s411299 · Cited by 6
“These vaccines have demonstrated a good safety profile and provide high efficacy against symptomatic COVID-19 infections.(5,6) The vaccines’ effectiveness was found to be 87% in preventing”
BackgroundFigueroa‐Hurtado, E., Ortíz‐Farias, D. L., Sada‐Ovalle, I., Maldonado-Ortiz, S. Y., Valdivieso‐Jiménez, J. A., & Cortés-Telles, A. (2022) · Respirology Case Reports · doi:10.1002/rcr2.920 · Cited by 3
“Adverse effects after the administration of the first dose of the vaccine were more frequent in previously infected female HCWs in contrast to what has been described in the results of the phase 3 trial of the BNT162b2 mRNA vaccine.(12) Adverse effects that develop after vaccination have received little attention from…”
ResultLapitan, M. C., Besa, J. J. V., Dans, L. F., Tolosa, M. T. S., & Alejandria, M. M. (2021) · Acta Medica Philippina · doi:10.47895/amp.v55i2.2875 · Cited by 4
Decoding pH-Driven Phase Transition of Lipid Nanoparticles
(2024) · doi:10.1101/2024.11.27.625717 · Cited by 4
Using peptide barcodes for simultaneous profiling of protein expression from mRNA
Kumano, S., Tanaka, K., Akahori, R., Yanagiya, A., & Nojima, A. (2024) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9867 · Cited by 5
Zheng, Y., Li, Y., Zeyneloglu, C., Tian, W., Babayev, H., D’Avino, P., He, Y., Öğülür, İ., Biçer, C., Lu, G., et al. (2026) · Allergy · doi:10.1111/all.70314 · Cited by 6
“During the original SARS- CoV-2 strain epidemic, two doses of mRNA vaccines achieved 80%–90% efficacy in preventing infection [64].”
Madanat, L., Sager, M., O’Connor, D., Thapa, B., Aggarwal, N., Ghimire, B., Lauter, C. B., Maine, G. N., Sims, M. D., & Halalau, A. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s370080 · Cited by 4
Placke, J., Mertens, D., Tasdogan, A., Chorti, E., Schadendorf, D., Ugurel, S., Roesch, A., Stoffels, I., & Klode, J. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18847 · Cited by 5
Tilch, K., Pütz, S. M., Appel, K. S., Kraus, M., Lorenz‐Depiereux, B., Pilgram, L., Anton, G., Berger, S., Geisler, R., Haas, K., et al. (2023) · BMC Medical Ethics · doi:10.1186/s12910-023-00959-0 · Cited by 4
“Declining recruitment during the fourth wave of COVID-19 might also have been caused by the diminishing overall attention to the pandemic, resumption of other trial activities related to other diseases, and a shift in the hospitalized COVID-19 population toward vaccination opponents with a lower overall trust level in…”
BackgroundFirst Diagnosis of Immunoglobulin A Nephropathy Following SARS-CoV-2 mRNA Vaccination in Japan
Yokote, S., Ueda, H., Shimizu, A., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.10.012 · Cited by 4
“T he SARS-CoV-2 mRNA vaccine has been effective against COVID-19.(1,2) However, following massscale SARS-CoV-2 mRNA vaccination, several immune-mediated disorders, including newly diagnosed or exacerbated cases of IgA nephropathy (IgAN), have been reported worldwide.”
Jameson, A. P., Sebastian, T. M., & Jacques, L. R. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.171 · Cited by 4
Altarawneh, H. N., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Thani, A. A. A., Coyle, P. V., Kanaani, Z. A., et al. (2023) · medRxiv · doi:10.1101/2023.04.21.23288917 · Cited by 4
A global blockchain for recording high rates of COVID-19 vaccinations
Medina, J. H., Rojas‐Cessa, R., Dong, Z., & Umpaichitra, V. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107074 · Cited by 7
Mirghaderi, P., Salimi, M., Moharrami, A., Dolama, R. H., Mirghaderi, S. R., Ghaderi, M., Motififard, M., & Mortazavi, S. M. J. (2022) · Arthroplasty Today · doi:10.1016/j.artd.2022.09.005 · Cited by 4
“There are several COVID-19 vaccines available worldwide that have demonstrated high effectiveness in preventing the infection and lowering COVID-19-related deaths [20-27].”
Schell, T. L., & Caldera, F. (2024) · PubMed Central · Cited by 6
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022
Jeantin, L., Januel, É., Labauge, P. M., Maillart, É., Seze, J. D., Zéphir, H., Pelletier, J., Kerschen, P., Biotti, D., Heinzlef, O., et al. (2024) · Multiple Sclerosis Journal · doi:10.1177/13524585231218149 · Cited by 4
“…11–17 The emergence of new SARS-CoV-2 variants of varying severity, 18 the development of vaccines with efficacy against symptomatic infections, 19,20 and the subsequent massive vaccination campaigns launched in 2021 to stop the pandemic have changed the epidemiology, risk factors, and outcomes…”
BackgroundAssenza, G. E., Castaldi, B., Flocco, S. F., Luciani, G. B., Meliota, G., Rinelli, G., Vairo, U., & Favilli, S. (2021) · Congenital Heart Disease · doi:10.32604/chd.2021.016713 · Cited by 4
Słomka, S., Zięba, P., Rosiak, O., & Piekarska, A. (2023) · Vaccines · doi:10.3390/vaccines11101625 · Cited by 8
Statistical Power and Swallowing Rehabilitation Research: Current Landscape and Next Steps
Borders, J. C., Grande, A. A., & Troche, M. S. (2022) · Dysphagia · doi:10.1007/s00455-022-10428-2 · Cited by 5
Hobohm, L., Sagoschen, I., Barco, S., Schmidtmann, I. M., Espinola–Klein, C., Konstantinides, S., Münzel, T. F., & Keller, K. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3979659 · Cited by 4
Sami, S., Tenforde, M. W., Talbot, H. K., Lindsell, C. J., Steingrub, J. S., Shapiro, N. I., Ginde, A. A., Douin, D. J., Prekker, M. E., Erickson, H. L., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab319 · Cited by 4
How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?
Haller, M. J., Jacobsen, L. M., Posgai, A. L., & Schatz, D. (2021) · Diabetes · doi:10.2337/dbi20-0045 · Cited by 4
Li, X., Wu, B., Lu, X., Yang, J., Zhu, Y., Yamagata, H. M., Tong, E. C., Mitchell, M. J., & Han, X. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00043 · Cited by 5
Luo, X., Liu, J., Du, X., Yang, J., Jiang, X., Li, Z., Wu, Y., & Yang, Y. (2024) · Acta Materia Medica · doi:10.15212/amm-2023-0033 · Cited by 4
COVID-19 VACCINES: EVIDENCE, CHALLENGES AND THE FUTURE
Tanzi, E., Genovese, C., Tettamanzi, M., Fappani, C., Raviglione, M. C., & Amendola, A. (2021) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2021.62.1s3.2084 · Cited by 6
Keinan‐Boker, L., Fluss, R., Dichtiar, R., Rosenberg, A., Lassan, M. B., & Huppert, A. (2024) · Israel Journal of Health Policy Research · doi:10.1186/s13584-024-00609-9 · Cited by 4
Snook, M. L., Beigi, R. H., Legro, R. S., & Paules, C. I. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.05.083 · Cited by 4
Safety and Tolerability of mRNA COVID-19 Vaccines in Kidney Transplant Recipients
Ślizień, Z., Muchlado, M., Kubanek, A., et al. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.02.025 · Cited by 4
“guidelines on toxicity grading scales for healthy adult volunteers enrolled in preventive vaccine clinical trials [7,8].”
BackgroundMethodResultInfluentialKoç, İ. (2022) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2022.j041 · Cited by 5
Deming, M. E., Brown, E. R., McArthur, M. A., Schrag, S. J., Arvay, M. L., Humphrys, M. S., Ravel, J., Adelglass, J. M., Essink, B. J., Musante, D. B., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.100984 · Cited by 5
Kim, A., Kim, S., Song, J.-E., Hwang, S., Nam, E., & Kwon, K. T. (2023) · Vaccines · doi:10.3390/vaccines11020363 · Cited by 5
“[12,15] In this regard, a more robust immune response might have been induced upon subsequent administration, whereas immunity to the antigen might have been established after the first administration.”
BackgroundAtari, N., Erster, O., Shteinberg, Y. H., Asraf, H., Giat, E., Mandelboim, M., & Goldstein, I. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1113697 · Cited by 4
“The mRNA-based vaccines developed by Pfizer-BioNTech (COMIRNATY) and Moderna (SPIKEVAX) have initially proven to offer effective protection from severe disease caused by the wild type (WT) variant of SARS-CoV-2 (Polack et al., 2020; Baden et al., 2021; Bar-On et al., 2021).”
BackgroundMethodPopulation-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil
Paula, N. M., Conzentino, M. S., Gonçalves, A. C. A., da Silva, R., Weissheimer, K. V., Kluge, C. H. S., Marins, P. H. S. A., Camargo, H. S. C., Farias, L. R. P., Sant’Ana, T. P., et al. (2022) · Vaccines · doi:10.3390/vaccines11010021 · Cited by 4
“Clinical studies involving the vaccines in use in Brazil reported efficacy against symptomatic infection after the 2nd shot of 95% for BNT162b2 [4], 62–67% for ChAdOx1-S [5], 50–84% for CoronaVac [6] https://www.”
BackgroundEffectiveness and Safety of SARS-CoV-2 Vaccination in HIV-Infected Patients—Real-World Study
Bociąga‐Jasik, M., Lara, M., Raczyńska, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11050893 · Cited by 4
“HIV-infected people were eligible for Phase 2/3 of the latter and constituted 196 out of 44,000 participants enrolled in the study [13].”
BackgroundKim, H., Yoon, J., Chu, H., et al. (2022) · The Journal of Internal Korean Medicine · doi:10.22246/jikm.2022.43.4.779 · Cited by 4
“Natural Product Sciences 1986; 17(3):223-31.”
BackgroundCOVID-19 Vaccination for Pilots and Air Traffic Controllers
Kwon, Y. H. (2021) · The Korean Journal of Aerospace and Environmental Medicine · doi:10.46246/kjasem.210003 · Cited by 4
Aelvoet, J., Zhong, Z., Gomez, C. M. B., Aegerter, H., Louage, B., Lambrecht, B. N., Geest, B. G. D., & Schuijs, M. J. (2025) · Advanced Materials · doi:10.1002/adma.202415468 · Cited by 4
Li, H., Terrando, N., & Gelbard, H. A. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_24 · Cited by 4
Ursino, M., Villacampa, G. J., Rekowski, J., Dimairo, M., Solovyeva, O., Ashby, D., Berlin, J. D., Boix, O., Calvert, M., Chan, A., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102988 · Cited by 6
Martínez‐Zamora, M. Á., Feixas, G., Gràcia, M., Rius, M., Quintas, L., de Guirior, C., & Carmona, F. (2023) · Women s Health · doi:10.1177/17455057231176751 · Cited by 7
Poor immune response to inactivated COVID-19 vaccine in patients with hypertension
Yang, L., Zhang, Z., Guo, Q., Yang, L., & Ren, H. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1329607 · Cited by 4
Measuring the efficacy of a vaccine during an epidemic
Scala, A., & Cavallo, P. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290652 · Cited by 5
“Finally, we notice that in the vaccine trials that have occurred, it has been observed that antibodies in the vaccinated individuals take time to develop [16, 29]; thus, if also the efficacy of a vaccine in a single individual grows with time, an extra bias could be introduced in efficacy and effectiveness measurement…”
BackgroundInfluentialMori, A., Onozawa, M., Kobayashi, M., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18447 · Cited by 4
McCormick, D. W., Konkle, S. L., Magleby, R., Chakrabarti, A. K., Cherney, B., Lindell, K., Namageyo-Funa, A., Visser, S. N., Soto, R. A., Donnelly, M. A. P., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.066 · Cited by 5
Renal outcomes in IgA nephropathy following inactivated SARS-CoV-2 vaccination
Sun, K., Shang, D., Hao, C., & Lai, L. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02398-y · Cited by 4
A fatal case of COVID‐19 breakthrough infection due to the delta variant
Bignardi, E., Brogna, C., Capasso, C., & Brogna, B. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5232 · Cited by 4
Zhang, J. H., Zhang, X., Yao, Y., Zhou, J., Chen, D., Shen, Y., Gong, Q., Li, Z., Zhou, Z., Li, E., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2517814123 · Cited by 5
Nishida, H., Takai, S., Ito, H., Fukuhara, H., Nawano, T., Narisawa, T., Kanno, H., Yagi, M., Yamagishi, A., Sakurai, T., et al. (2023) · Clinical Transplantation · doi:10.1111/ctr.14952 · Cited by 5
Germany's current COVID-19 crisis is mainly driven by the unvaccinatedPreprint
Maier, B., Wiedermann, M., Burdinski, A., Klamser, P., Jenny, M., Betsch, C., & Brockmann, D. (2021) · medRxiv · doi:10.1101/2021.11.24.21266831 · Cited by 4
Özenen, G. G., Bal, Z. Ş., Bilen, N. M., Arslan, S. Y., Ak, G., Koç, G., Çiçek, C., Kurugöl, Z., & Özkınay, F. (2022) · Journal of Tropical Pediatrics · doi:10.1093/tropej/fmac041 · Cited by 4
Health Technology Assessment of mRNA Vaccines: Clinical, Economic, and Public Health Implications
Genovese, G., Rizzo, C. E., & Genovese, C. (2025) · Vaccines · doi:10.3390/vaccines13101045 · Cited by 5
“However, these early promising results did not initially lead to substantial investment in mRNA therapeutics, largely due to concerns about mRNA instability, high innate immunogenicity, and inefficient in vivo delivery [9–11].”
Eldi, P., Cooper, T. H., Prow, N. A., Liu, L., Heinemann, G. K., Zhang, V. J., Trinidad, A. D., Guzman‐Genuino, R. M., Wulff, P., Hobbs, L., et al. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12539 · Cited by 6
Fast Progression of Diabetic Retinopathy with SARS-CoV-2 Infection
Akduman, Y., Anderson, W., & Saxena, S. (2021) · EMJ Diabetes · doi:10.33590/emjdiabet/20-00254 · Cited by 4
Houston, K. D., Hartnett, J., & Rose, S. J. (2023) · Data in Brief · doi:10.1016/j.dib.2023.109287 · Cited by 6
“[5]–[8] Although the COVID-19 vaccination has been deemed safe [9], [10]and able to alleviate the degree of new and acute infections, research on the side effects experienced, specifically GI symptomology, following the receipt of the COVID-19 vaccination is limited particularly for people with pre-existing medical co…”
Wagenhäuser, I., Almanzar, G., Förg, F. B., Stein, A., Eiter, I., Reusch, J., Mees, J., Herzog, A. L., Vogel, U. F., Frey, A., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.07.033 · Cited by 9
Alexander, J. L., Liu, Z., Sandoval, D. M., Reynolds, C. J., Ibraheim, H., Anandabaskaran, S., Saifuddin, A., Seoane, R., Anand, N., Nice, R., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4172071 · Cited by 4
Safety and efficacy of RNA vaccines: State of the art
Blagov, A. V., Bukaeva, A. A., Makarov, V. V., & Bochkaeva, Z. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-sae-2320 · Cited by 5
Evolutionary dynamics of voluntary vaccination for imperfect multi-efficacy vaccines
Hu, S., Liu, Y., & Wu, B. (2024) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2023.0743 · Cited by 5
Coronavirus Variants—Will New mRNA Vaccines Meet the Challenge?
Welsh, J. (2021) · Engineering · doi:10.1016/j.eng.2021.04.005 · Cited by 4
“Large clinical trials have shown unprecedented effectiveness for the two US-authorized mRNA COVID-19 vaccines, both about 95% after the second dose [16].”
BackgroundIntroduction to RNA Vaccines Post COVID-19
Kramps, T. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_1 · Cited by 6
Yoon, E.-H., Kim, D., Jeon, H., Kwon, Y., Jang, Y., Kim, S., & Hwang, K. Y. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.043 · Cited by 4
“High efficacy and safety of the messenger RNA (mRNA) vaccines BNT162b2 (BioNTech-Pfizer) and mRNA-1273 (Moderna/NIAID) against COVID-19 have been demonstrated in clinical trials [1-3].”
BackgroundHe, Q., Liu, S., Liang, Z., Lu, S., Cun, W., & Mao, Q. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2152388 · Cited by 4
“[1] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
BackgroundAkman, B., & Ahmet Turan, K. A. Y. A. (2022) · Journal of Clinical Ultrasound · doi:10.1002/jcu.23390 · Cited by 4
“In the phase 2/3 data of the BNT162b2 vaccine, it has been shown that young people more frequently use antipyretic or analgesic drugs than older people after vaccination.(16) Also in our study NSAID users were younger than non-users, and were all female.”
BackgroundOcular Complications after COVID-19 Vaccination: A Systematic Review
Hurissi, E., Abuallut, I., Dibaji, M., Jaly, A. A., Alhazmi, A., Abuageelah, B. M., Alameer, K. M., & Alyami, Y. M. (2024) · Medicina · doi:10.3390/medicina60020249 · Cited by 9
“COV2, Janssen Johnson & Johnson; ChAdOx1 nCoV-19/AZD1222, Oxford-AstraZeneca, Oxford, UK), mRNA (mRNA-1273, Moderna, Cambridge, MA, USA), and protein subunits (NVXCoV2373, Novavax, Gaithersburg, MD, USA) [3].”
Ospina, A. V., Bruges, R. E., Triana, I. C., Sánchez, G., Barrero, A., Mantilla, W. A., Ramos, P., Bernal, L., Aruachán, S., González, M., et al. (2023) · Journal of Cancer · doi:10.7150/jca.79969 · Cited by 5
“Ben-Aharon and colleagues studied the effectiveness of the BNT162b2 vaccine in a cohort of cancer patients (n=232) compared with a previously healthy control group of health workers (n=261).”
InfluentialSafety and efficacy of mRNA vaccines: a mechanistic and public health perspective
Blakney, A. K., Top, K. A., Cowling, B. J., Larson, H. J., Shattock, R. J., & Sadarangani, M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00512-x · Cited by 18
The “LLQY” Motif on SARS-CoV-2 Spike Protein Affects S Incorporation into Virus Particles
Du, S., Xu, W., Wang, Y., Li, L., Hao, P., Tian, M., Wang, M., Li, T., Wu, S.-P., Liu, Q., et al. (2022) · Journal of Virology · doi:10.1128/jvi.01897-21 · Cited by 6
“(35, 36), mRNA nucleic acid vaccines (37), and protein subunit vaccines (38), have contributed to prevention and control of SARS-CoV-2.”
BackgroundTranslating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research
Choudhury, N. J., Riely, G. J., Sabbatini, P. J., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.001 · Cited by 4
A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform
Jiang, Y., Sanyal, M., Hussein, N. A., Baghdasaryan, A., Zhang, M., Wang, F., Ren, F., Li, J., Zhu, G., Meng, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.adp5539 · Cited by 8
Kaba, M., Koyuncu, M., Schneider, S. O., & Sutter, M. (2024) · European Economic Review · doi:10.1016/j.euroecorev.2024.104818 · Cited by 5
Trends and Hotspots in Nanomedicine Applications for Pain: A Bibliometric Analysis from 1999 to 2024
Wang, S., He, Y., & Huang, Y. (2025) · ACS Omega · doi:10.1021/acsomega.4c10893 · Cited by 4
Chambers, C. (2021) · Canadian Journal of Public Health · doi:10.17269/s41997-021-00554-z · Cited by 8
Spadaccini, M., Canziani, L. M., Aghemo, A., Lleò, A., Maselli, R., Anderloni, A. A., Carrara, S., Fugazza, A., Pellegatta, G., Galtieri, P. A., et al. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12103 · Cited by 3
Jabbour, G., Rego, S., Nguyenkhoa, V., & Dakshanamurthy, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.11.459907 · Cited by 4
“While the currently approved vaccines have been shown to offer effective protection against the original SARS-CoV-2 strain in clinical trials [12,13,14], multiple variants that differ from those present during clinical trials are now spreading worldwide and continue to emerge.”
BackgroundOrunta, C. P., Ndu, C. O., Ijioma, C. E., Ogedegbe, O. J., Ogundipe, F. A., & Eze-Njoku, C. (2024) · Cureus · doi:10.7759/cureus.64984 · Cited by 6
Segal, R. M., Shavit, R., Kidon, M. I., Offengenden, I., Machnes‐Maayan, D., Lifshitz, Y., Niznik, S., & Agmon‐Levin, N. (2022) · Life · doi:10.3390/life12122021 · Cited by 5
“Soon after the accelerated development of these vaccines, the global immunization programs were initiated throughout the world, as well as in Israel, with the aim of controlling the pandemic [1,2].”
BackgroundLi, T., Gandra, S., Reske, K. A., et al. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.31 · Cited by 4
“Hydroxychloroquine 4 (2) 1 (3) 3 (2) 1.”
InfluentialCOVID ‐19: The disease, the vaccine and the heart
Turner, C. (2023) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.16407 · Cited by 4
Automated Online Direct mRNA Sequence Mapping Using Partial RNase T1 Digests
Dale, J. S., Welbourne, E. N., Evans, C. A., et al. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c08110 · Cited by 4
Ma, Q., Huang, F., Guo, W., Feng, K., Huang, T., & Cai, Y. (2023) · Life · doi:10.3390/life13061304 · Cited by 6
“The immunogenicity of mRNA-1273 lasts for at least 3 months [82], whereas that of BNT162b2 lasts for at least 2 months [12].”
BackgroundTang, J., Gong, D., Li, H., & Li, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.039 · Cited by 7
“Lipid nanoparticles (LNPs), for instance, are self-assembled nano-carriers highly effective for nucleic acid drug delivery ( e.g. , mRNA, siRNA), famously serving as the crucial platform for COVID-19 mRNA vaccines, demonstrating unprecedented efficacy 50,51 .”
Zerbo, O., FIREMAN, B. H., & Klein, N. P. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1984891 · Cited by 6
Jia, K. M., Boyer, C., Wallinga, J., & Lipsitch, M. (2025) · Epidemiology · doi:10.1097/ede.0000000000001839 · Cited by 9
Shenoy, E. S., Wickner, P. G., West, L. R., Banerji, A., Blumenthal, K. G., Centi, A. J., Gottlieb, A., Hashimoto, D. M., Kim, E., Kim, M., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.449 · Cited by 4
Machine learning for nanoparticle-based imaging: From rational design to precision diagnosis
Kang, N., Li, Z., Tan, F., Liu, Z., Yang, Y., Qian, X., & Zhang, Q. (2025) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2025.103773 · Cited by 5
Influence of Covid‐19 vaccination on immune‐mediated skin diseases
Alelq, N. A., Kubieniec, M. E., French, L. E., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18388 · Cited by 4
Oktavianawati, I., Santoso, M., Bakar, M. F. A., Kim, Y., & Fatmawati, S. (2023) · Applied Biological Chemistry · doi:10.1186/s13765-023-00842-x · Cited by 7
Igarashi, A., Shimizu, T., Takeda, M., Ida, Y., Ishida, A., Yuda, K., Yuda, K., Wajima, H., Kobayashi, A., Nakashizuka, H., et al. (2023) · Cornea · doi:10.1097/ico.0000000000003335 · Cited by 4
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.